- Home
- STEP vs VKTX Comparison
STEP vs VKTX Comparison
Compare STEP & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEP
- VKTX
- Stock Information
- Founded
- STEP 2007
- VKTX 2012
- Country
- STEP United States
- VKTX United States
- Employees
- STEP N/A
- VKTX N/A
- Industry
- STEP Finance/Investors Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- STEP Finance
- VKTX Health Care
- Exchange
- STEP Nasdaq
- VKTX Nasdaq
- Market Cap
- STEP 4.4B
- VKTX 4.7B
- IPO Year
- STEP 2020
- VKTX 2015
- Fundamental
- Price
- STEP $62.84
- VKTX $32.37
- Analyst Decision
- STEP Hold
- VKTX Strong Buy
- Analyst Count
- STEP 8
- VKTX 12
- Target Price
- STEP $63.94
- VKTX $106.75
- AVG Volume (30 Days)
- STEP 430.3K
- VKTX 3.8M
- Earning Date
- STEP 02-06-2025
- VKTX 02-05-2025
- Dividend Yield
- STEP 1.67%
- VKTX N/A
- EPS Growth
- STEP N/A
- VKTX N/A
- EPS
- STEP 0.63
- VKTX N/A
- Revenue
- STEP $800,276,000.00
- VKTX N/A
- Revenue This Year
- STEP $25.40
- VKTX N/A
- Revenue Next Year
- STEP $19.23
- VKTX N/A
- P/E Ratio
- STEP $100.43
- VKTX N/A
- Revenue Growth
- STEP 48.87
- VKTX N/A
- 52 Week Low
- STEP $32.33
- VKTX $23.11
- 52 Week High
- STEP $70.38
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- STEP 52.48
- VKTX 33.65
- Support Level
- STEP $61.05
- VKTX $32.77
- Resistance Level
- STEP $65.05
- VKTX $34.78
- Average True Range (ATR)
- STEP 1.69
- VKTX 2.05
- MACD
- STEP 0.15
- VKTX 0.27
- Stochastic Oscillator
- STEP 59.49
- VKTX 33.46
About STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.